Limula SA

Limula SA is a Swiss life science tools company that provides a closed, automated platform designed for the manufacturing of highly personalized cell and gene therapies, such as CAR-T treatments. Founded in 2020 and based in Lausanne, the company integrates bioreactor and mechatronics technologies to streamline the production process, transitioning from manual, open methods to standardized, automated workflows. Their product suite includes LimGROW for research and process development, and LimONE for clinical-grade, end-to-end commercial production. By combining precision engineering with cell therapy expertise, Limula aims to enable seamless technology transfer and faster time-to-market for therapeutic developers.

This technology is critical for overcoming the manufacturing challenges associated with personalized medicine, where reliability, scalability, and cost-efficiency are essential. By utilizing a closed, automated system, Limula helps partners reduce human error, maintain batch-to-batch consistency, and lower the reliance on highly classified cleanroom infrastructure. Their solution supports the entire product lifecycle—from early-stage research to commercial manufacturing—helping pharmaceutical and biotech companies simplify the complexity of clinical production and broaden patient access to life-saving treatments.